DeepMed Research

Otsuka Beijing Research Institute

🇨🇳China

Country: 🇨🇳China

Ownership: Subsidiary

Established: 2003-08-29

Employees: -

Market Cap: -

Website: http://www.obri.com.cn

Clinical Trials

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects with Myelodysplastic Syndromes

Phase 1

Recruiting

Conditions: Myelodysplastic Syndromes

Interventions: Drug: IV Decitabine
Drug: Decitabine and cedazuridine
Drug: only Decitabine and cedazuridine

First Posted Date: 2023-10-19

Last Posted Date: 2025-03-25

Lead Sponsor: Otsuka Beijing Research Institute

Target Recruit Count: 72

Registration Number: NCT06091267

Locations: 🇨🇳
The First Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type

Phase 2

Completed

Conditions: Irritable Bowel Syndrome of Diarrhea Type (IBS-D)

Interventions: Drug: placebo
Drug: OPS-2071

First Posted Date: 2023-06-28

Last Posted Date: 2025-04-03

Lead Sponsor: Otsuka Beijing Research Institute

Target Recruit Count: 87

Registration Number: NCT05923892

Locations: 🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China

To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients with AD

Phase 3

Completed

Conditions: Atopic Dermatitis (AD)

Interventions: Drug: 1% OPA-15406 Ointment
Other: 0% OPA-15406 Vehicle

First Posted Date: 2022-12-28

Last Posted Date: 2025-03-25

Lead Sponsor: Otsuka Beijing Research Institute

Target Recruit Count: 270

Registration Number: NCT05667623

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD

Phase 3

Completed

Conditions: Atopic Dermatitis (AD)

Interventions: Drug: 0.3% OPA-15406 Ointment
Drug: 1% OPA-15406 Ointment
Other: 0% OPA-15406 vehicle

First Posted Date: 2022-12-14

Last Posted Date: 2025-03-25

Lead Sponsor: Otsuka Beijing Research Institute

Target Recruit Count: 240

Registration Number: NCT05650320

Locations: 🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, Beijing, China

OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects

Phase 3

Completed

Conditions: Open Angle Glaucoma or Ocular Hypertension

Interventions: Drug: 0.005% Latanoprost
Drug: OPC-1085EL

First Posted Date: 2022-10-17

Last Posted Date: 2025-03-27

Lead Sponsor: Otsuka Beijing Research Institute

Target Recruit Count: 204

Registration Number: NCT05583474

Locations: 🇨🇳
Eye & ENT Hospital of Fudan University, Shanghai, China

OPC-61815 in Healthy Chinese Male Subjects

Phase 1

Completed

Conditions: Healthy Adult Male

Interventions: Drug: OPC-61815 injection

First Posted Date: 2022-06-30

Last Posted Date: 2023-10-13

Lead Sponsor: Otsuka Beijing Research Institute

Target Recruit Count: 18

Registration Number: NCT05439148

Locations: 🇨🇳
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing, China

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Phase 2

Active, not recruiting

Conditions: Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: Ponatinib 30mg OD
Drug: Ponatinib 45mg OD

First Posted Date: 2020-01-18

Last Posted Date: 2025-04-04

Lead Sponsor: Otsuka Beijing Research Institute

Target Recruit Count: 93

Registration Number: NCT04233346

Locations: 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China

and more 11 locations

Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Brexpiprazole
Drug: Aripiprazole

First Posted Date: 2019-03-14

Last Posted Date: 2025-04-18

Lead Sponsor: Otsuka Beijing Research Institute

Target Recruit Count: 371

Registration Number: NCT03874494

Locations: 🇨🇳
No.15 Yanyin Road, Yanta District, Xi'an, Shanxi, China

The Pharmacokinetics, and Safety of Brexpiprazole Tablets in Chinese Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Brexpiprazole

First Posted Date: 2018-11-07

Last Posted Date: 2023-11-01

Lead Sponsor: Otsuka Beijing Research Institute

Target Recruit Count: 10

Registration Number: NCT03734302

Locations: 🇨🇳
Beijing Anding Hospital of Capital Medical University, Beijing, Beijing, China

The Pharmacokinetics, Tolerability and Safety of Brexpiprazole in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Health

Interventions: Drug: Brexpiprazole

First Posted Date: 2018-11-07

Last Posted Date: 2023-11-01

Lead Sponsor: Otsuka Beijing Research Institute

Target Recruit Count: 30

Registration Number: NCT03734354

Locations: 🇨🇳
Beijing Anding Hospital of Capital Medical University, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy